Which type of von Willebrand disease (VWD) requires the use of DDAVP?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Study for the Oral and Maxillofacial Surgery In-Service Training (OMSITE) Test. Prepare with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

Which type of von Willebrand disease (VWD) requires the use of DDAVP?

Explanation:
Type 1 von Willebrand disease (VWD) is characterized by a partial quantitative deficiency of von Willebrand factor (VWF), which is essential for platelet adhesion and maintaining hemostasis. In this condition, the levels of VWF are lower than normal but still present, which often allows for treatment with desmopressin (DDAVP). DDAVP stimulates the release of VWF from endothelial cells, increasing its levels and improving platelet function, which can help manage bleeding episodes effectively. The use of DDAVP is particularly effective in type 1 VWD because the patient still has some ability to produce VWF, albeit at reduced levels. By boosting the levels of VWF in the bloodstream, DDAVP effectively manages the symptoms associated with this condition. In contrast, other types of VWD, such as type 2 (which involves a qualitative defect in VWF) and type 3 (which is a complete deficiency of VWF), do not respond to DDAVP in the same way. Type 2 often requires more specialized treatment approaches, and type 3 patients typically need to receive VWF/factor VIII concentrates since they have little to no VWF. Type 4 is not a recognized classification of

Type 1 von Willebrand disease (VWD) is characterized by a partial quantitative deficiency of von Willebrand factor (VWF), which is essential for platelet adhesion and maintaining hemostasis. In this condition, the levels of VWF are lower than normal but still present, which often allows for treatment with desmopressin (DDAVP). DDAVP stimulates the release of VWF from endothelial cells, increasing its levels and improving platelet function, which can help manage bleeding episodes effectively.

The use of DDAVP is particularly effective in type 1 VWD because the patient still has some ability to produce VWF, albeit at reduced levels. By boosting the levels of VWF in the bloodstream, DDAVP effectively manages the symptoms associated with this condition.

In contrast, other types of VWD, such as type 2 (which involves a qualitative defect in VWF) and type 3 (which is a complete deficiency of VWF), do not respond to DDAVP in the same way. Type 2 often requires more specialized treatment approaches, and type 3 patients typically need to receive VWF/factor VIII concentrates since they have little to no VWF. Type 4 is not a recognized classification of

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy